TNF and rheumatoid arthritis: Another retrospective cohort study, which followed RA patients for two years after the initiation of a TNF-α antagonist, detected a risk reduction of clinical vertebral fractures (HR 0.71, adjusted for baseline glucocorticoid use); the references were users of csDMARDs [102].